标题
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
作者
关键词
-
出版物
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 33, Issue 1, Pages 225-237
出版商
American Society of Nephrology (ASN)
发表日期
2021-11-04
DOI
10.1681/asn.2021070942
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial
- (2019) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Rajiv Agarwal et al. LANCET
- Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom
- (2019) Cecilia Linde et al. Journal of the American Heart Association
- Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
- (2018) Csaba P Kovesdy et al. EUROPEAN HEART JOURNAL
- Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
- (2018) Akshay S. Desai et al. JOURNAL OF CARDIAC FAILURE
- Renal mineralocorticoid receptor and electrolyte homeostasis
- (2015) Andrew S. Terker et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist
- (2014) Orly Vardeny et al. Circulation-Heart Failure
- Management of hyperkalaemia in chronic kidney disease
- (2014) Csaba P. Kovesdy Nature Reviews Nephrology
- Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
- (2014) Ivana Lazich et al. SEMINARS IN NEPHROLOGY
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started